Rezolute Application for Hypoglycemia Treatment Gets FDA Clearance
By Denny Jacob
Rezolute received a U.S. Food and Drug Administration clearance for its investigational new drug application for RZ358, a treatment for hypoglycemia in patients with tumor hyperinsulinism.
The late-stage rare disease company said on Monday that it's initiating start-up activities for the study which will primarily be conducted in the U.S. with patient enrollment planned to start in the first half of 2025.
RZ358 is also being studied in a continuing phase 3 clinical trial in patients with congenital tumor hyperinsulinism. Topline data from that study is expected in mid-2025, it said.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 05, 2024 08:23 ET (12:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks